MP’s Vote to Remain in EMA Post-Brexit
MP’s have voted in favour of continued involvement with the EMA following Brexit. Now, a deal must be secured for the UK so that it can remain as an active participant in the EMA following the UK’s exit from the European Union. A deal in which the government will be making an “appropriate financial contribution”.
One of the consequences of Brexit is that EMA will relocate to Amsterdam, the Netherlands, where it will take up its operations on 30 March 2019 at the latest.
The Drug Safety Research Unit (DSRU) welcomed the decision in stating that: “The DSRU believes that the overall aim should be to ensure that citizens of the UK and the EU continue to gain access to the best and most innovative medicines. The DSRU will continue to support the MHRA (the UK medicines regulator) and the EMA in their efforts to achieve this aim.”
“Parliament has sent a clear message that patients and public health should be a top priority for the Government in these negotiations” Chief executives of the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Assocation (BIA), Mike Thompson and Steve Bates, said in a joint statement.
“Every month, 37 million packs of medicine arrive in the UK from the EU and 45 million move the other way. Therefore, it is essential that the UK continues to participate in the EMA after Brexit, as set out in the Brexit White Paper and in the prime minister’s Mansion House speech.”